Matinas BioPharma Holdings, Inc.
MTNB
$0.59
-$0.05-7.84%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -100.00% | -- | -- | -97.53% | -35.17% |
| Gross Profit | 100.00% | -- | -- | 97.53% | 35.17% |
| SG&A Expenses | -3.73% | -26.38% | -25.57% | -24.23% | -25.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.38% | -64.00% | -68.54% | -67.03% | -31.41% |
| Operating Income | 60.38% | 64.00% | 68.54% | 67.03% | 31.41% |
| Income Before Tax | 77.54% | 64.16% | 8.29% | 71.57% | -60.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.33% | 64.16% | 8.29% | 71.57% | -58.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.33% | 64.16% | 8.29% | 71.57% | -58.69% |
| EBIT | 60.38% | 64.00% | 68.54% | 67.03% | 31.41% |
| EBITDA | 59.56% | 63.23% | 68.26% | 66.82% | 31.82% |
| EPS Basic | 81.64% | 53.39% | 10.09% | 75.70% | -35.51% |
| Normalized Basic EPS | 63.52% | 66.80% | 67.43% | 71.38% | 34.40% |
| EPS Diluted | 81.64% | 53.39% | 10.09% | 75.70% | -35.51% |
| Normalized Diluted EPS | 63.52% | 66.80% | 67.43% | 71.38% | 34.40% |
| Average Basic Shares Outstanding | 23.47% | 7.90% | 2.01% | 17.02% | 17.11% |
| Average Diluted Shares Outstanding | 23.47% | 7.90% | 2.01% | 17.02% | 17.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |